Trials / Terminated
TerminatedNCT01793649
A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects
A Phase 1, Randomized, Double-Blind, Cross-Over, Vehicle-Controlled, Single-Dose Study To Characterize The Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) In Healthy Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, double-blind, cross-over, vehicle-controlled study to determine whether GS-5737 in 2.8% saline accelerates mucociliary clearance (MCC) in healthy subjects, compared to vehicle of 2.8% saline alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GS-5737 | A single dose of GS-5737 in 2.8% saline |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2013-02-15
- Last updated
- 2014-03-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01793649. Inclusion in this directory is not an endorsement.